Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Omicron: a drug developer's perspective.

Emerging microbes & infections - 1 Dec 2022

Fang Fang Flora, Shi Pei-Yong

Abstract excerpt

We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to COVID-19 Drug Treatment
Share to COVID-19 Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Immune Evasion

Share to Receptors, Virus

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34951568
DOI: 10.1080/22221751.2021.2023330
PMCID: PMC8741250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Omicron: a drug developer's perspective.PMID 34951568Read ↗

In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.Semantic proximity Read ↗

"Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.Semantic proximity Read ↗

COVID‐19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS‐CoV‐2Semantic proximity Read ↗

Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read ↗

A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in TherapiesSemantic proximity Read ↗

Evolution of the SARS-CoV-2 Omicron spikeSemantic proximity Read ↗

Mutations in the spike RBD of SARS-CoV-2 omicron variant may increase infectivity without dramatically altering the efficacy of current multi-dosage vaccinationsSemantic proximity Read ↗

The puzzling mutational landscape of the SARS-2-variant Omicron.Semantic proximity Read ↗

Structural basis of Omicron immune evasion: A comparative computational study of Spike protein-Antibody interactionSemantic proximity Read ↗

Spike mutations of the SARS-CoV-2 Omicron: more likely to occur in the epitopesSemantic proximity Read ↗

Attenuated replication and pathogenesis of SARS-CoV-2 B.1.1.529 OmicronSemantic proximity Read ↗

Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.